Serpin A-12 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Serpin A-12 (Vaspin/SERPINA12; UniProt Q8IW75), expressed in HEK293 cells. Suited for KLK7 inhibition assays, adipokine functional studies, and antibody validation as a defined positive control.
Expression system
HEK293
Cat. #
REC-SerpinA12

In stock

SKU
REC-SerpinA12
$498.00

Target Overview

Serpin A-12, encoded by SERPINA12 and commonly referred to as vaspin (visceral adipose tissue-derived serine protease inhibitor), is a 414-amino-acid secreted member of the serine protease inhibitor (serpin) superfamily (UniProt Q8IW75). Its biochemically defined target protease is kallikrein-related peptidase 7 (KLK7), which it inhibits via a canonical serpin suicide-substrate mechanism. This recombinant form is produced in HEK293 mammalian cells, providing glycosylation and folding conditions appropriate for a secreted serpin, and is therefore well suited to functional assays that depend on native tertiary structure. In the laboratory, researchers use this recombinant to measure inhibitory activity against recombinant KLK7 in fluorogenic peptide-substrate assays, to generate inhibition constants (Ki), and to determine IC50 values for competing small-molecule or peptide inhibitors of the vaspin–KLK7 interaction. Because Serpin A-12 is released from white adipose tissue and circulates as an adipokine, it is also used as a reference standard in binding assays, surface plasmon resonance (SPR) experiments, and enzyme-linked immunosorbent assays (ELISAs) characterising vaspin interactions with its target protease or with putative receptor candidates. For researchers performing antibody validation, this recombinant provides a well-defined positive control antigen. It can be paired directly with the Triple Point Biologics matched antibody (RP-SerpinA12) — available via the cross-linked product page — to confirm detection specificity by Western blot or immunohistochemistry under standardised conditions. The HEK293 expression system supports post-translational modifications absent from bacterial or insect-cell counterparts, making this reagent appropriate where glycan-dependent epitope recognition or folding-sensitive inhibitor activity is a consideration.

Background

Serpin A-12 (vaspin) was first identified as an adipokine produced preferentially in visceral white adipose tissue and subsequently shown to function as a specific serine protease inhibitor of KLK7. As a secreted protein, it enters circulation and has been studied as a humoral signal linking adipose tissue biology to systemic metabolic regulation. The mechanistic basis of its insulin-sensitising effect in rodent models has been attributed, at least in part, to suppression of KLK7-mediated proteolytic activity in adipose depots, although the downstream signalling cascade linking KLK7 inhibition to glucose homeostasis remains an active area of investigation. Beyond metabolic research, SERPINA12 has attracted attention in dermatology. KLK7 is a well-characterised regulator of skin barrier desquamation, and loss-of-function mutations in SERPINA12 have been associated with Nagashima-type palmoplantar keratoderma (NPPK), a recessive skin disorder characterised by hyperkeratosis of palms and soles. Rapid genetic diagnostic strategies for NPPK involving SERPINA12 variant detection have been described in the recent literature (Zhang J et al., J Dermatol, 2026, PMID 41891421). Separately, the role of vaspin in psoriasis and broader skin immunobiology is under active characterisation, with molecular mechanisms in adipocytes and keratinocytes being delineated (Xiao Z et al., Front Immunol, 2026, PMID 42125668). In the cardiometabolic arena, vaspin is studied alongside other adipokines — such as PAI-1 — for its associations with components of metabolic syndrome, including insulin resistance, dyslipidaemia, and cardiovascular risk markers. Meta-analyses of case-control studies have examined associations between the SERPINA12 rs2236242 polymorphism and metabolic syndrome susceptibility (Lim WY et al., Metab Syndr Relat Disord, 2026, PMID 41852039). Proteomic profiling studies have also identified vaspin among circulating biomarker candidates associated with cardiovascular health trajectories from childhood into adolescence (Lin Z et al., Eur J Prev Cardiol, 2026, PMID 41934237). Taken together, published research positions Serpin A-12 as a multifunctional adipokine investigated across metabolic, dermatological, and cardiovascular research contexts. This recombinant reagent supports in vitro dissection of vaspin biology — from enzymatic inhibition kinetics with KLK7 to binding characterisation and antibody validation — without the structural ambiguities introduced by prokaryotic expression systems.

Applications

  • KLK7 serine protease inhibition assay using fluorogenic peptide substrates
  • Inhibitor IC50 and Ki determination for vaspin–KLK7 competitive displacement
  • Antibody validation positive control for Western blot (pairs with TP Biologics RP-SerpinA12)
  • Antibody validation positive control for immunohistochemistry (pairs with TP Biologics RP-SerpinA12)
  • ELISA standard or capture antigen for quantification of vaspin in biological samples
  • Surface plasmon resonance (SPR) binding characterisation of vaspin interactions with KLK7 or candidate receptors
  • Adipokine functional studies — comparison of serpin activity under metabolic model conditions
  • Substrate for mass spectrometry-based identification of vaspin-interacting proteases or binding partners

References

  1. Xiao Z et al. SERPINA12 in skin: molecular mechanisms and roles in adipocytes, psoriasis, and palmoplantar keratoderma. Front Immunol. 2026. doi:10.3389/fimmu.2026.1812302. PMID 42125668.
  2. Kocabas S. The expanding landscape of adipokines: emerging roles of PAI-1 and vaspin in cardiometabolic diseases. Front Endocrinol (Lausanne). 2026. doi:10.3389/fendo.2026.1787458. PMID 41970985.
  3. Lin Z et al. Cardiovascular health across childhood and adolescence and proteomic biomarkers in late adolescence. Eur J Prev Cardiol. 2026. doi:10.1093/eurjpc/zwag176. PMID 41934237.
  4. Zhang J et al. Development of an ARMS-qPCR Strategy for the Rapid Genetic Diagnosis of Nagashima-Type Palmoplantar Keratoderma. J Dermatol. 2026. doi:10.1111/1346-8138.70239. PMID 41891421.
  5. Lim WY et al. Association of Vaspin rs2236242 with Metabolic Syndrome: A Meta-Analysis of Case-Control Studies. Metab Syndr Relat Disord. 2026. doi:10.1177/15578518261429025. PMID 41852039.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; blood plasma

Frequently Asked Questions

What is the expected molecular weight of recombinant Serpin A-12 on SDS-PAGE and Western blot?

The SERPINA12-encoded polypeptide is 414 amino acids with a predicted unglycosylated MW of ~47 kDa. Because this recombinant is produced in HEK293 cells under native secretory conditions, N-linked glycosylation shifts the apparent MW on reducing SDS-PAGE to approximately 55–60 kDa. On Western blot using our matched rabbit polyclonal (RP-SerpinA12), you should expect a diffuse band in that 55–60 kDa range, consistent with glycoprotein heterogeneity. Deglycosylation with PNGase F will collapse this to the ~47 kDa core polypeptide if a sharper reference band is needed.

Is recombinant Serpin A-12 (vaspin) produced as a full-length protein or a processed isoform?

This recombinant corresponds to the full-length mature secreted form of Serpin A-12 (UniProt Q8IW75, residues 24–414 after signal peptide cleavage). No reactive-center loop (RCL) pre-cleavage or latency-inducing modifications are introduced during production. The protein is purified in its native, inhibitory-competent conformation and has not been converted to the cleaved or latent serpin form, which is important to confirm before kinetic experiments — cleaved serpin runs ~2–3 kDa smaller on SDS-PAGE under reducing conditions.

What protease does Serpin A-12 (vaspin) inhibit and what substrate can I use to measure KLK7 inhibition activity?

Serpin A-12 inhibits kallikrein-related peptidase 7 (KLK7) via a covalent, irreversible suicide-substrate mechanism. To measure inhibitory activity, pre-incubate Serpin A-12 with recombinant KLK7 for 15–30 min at 37 °C in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, then add the fluorogenic substrate Suc-LLVY-AMC (or Ac-Lys-Pro-Arg-AMC for higher KLK7 selectivity) at 100–200 µM. Monitor fluorescence at Ex 380 nm / Em 460 nm. Residual KLK7 activity relative to a no-inhibitor control directly reports Serpin A-12 inhibitory efficiency.

What starting concentration of recombinant Serpin A-12 should I use for a KLK7 inhibition or IC50 assay?

For inhibition constant (Ki) determination, titrate Serpin A-12 across a 0.1–10× molar excess relative to your KLK7 concentration; a practical starting range is 50–500 nM Serpin A-12 with 50–100 nM KLK7. For competitive IC50 experiments where Serpin A-12 is the reference inhibitor, fix it at your empirically determined Ki and vary the competitor concentration. Because serpins bind stoichiometrically rather than catalytically, mass-based excess rather than catalytic excess determines titration endpoints — keep this in mind when designing dilution series.

Can I use recombinant Serpin A-12 as a positive control for Western blot with the RP-SerpinA12 rabbit polyclonal antibody?

Yes, and this is one of the most straightforward use cases. Load 50–200 ng of this recombinant per lane alongside your cell or tissue lysate. The matched rabbit polyclonal antibody (RP-SerpinA12; /anti-serpin-a12-rabbit-polyclonal-antibody) is guaranteed compatible — both the recombinant and antibody originate from the same TPB program. At 50–100 ng loaded, you should see a clean 55–60 kDa band under standard reducing, denaturing conditions. This also serves as a reliable molecular weight reference for interpreting endogenous vaspin bands in adipose tissue lysates.

How much recombinant Serpin A-12 should I load for Western blot antibody validation with RP-SerpinA12?

For antibody validation purposes — particularly if you are building an antibody validation data set or submitting to a journal requiring positive controls — load a two-point titration: 50 ng and 200 ng per lane. At 50 ng, RP-SerpinA12 should produce a detectable band with signal-to-noise suitable for publication. At 200 ng, band intensity confirms linearity. Running these alongside a KO or knockdown lysate (negative control) satisfies most antibody validation guidelines. The recombinant's purity of >90–95% by SDS-PAGE ensures the band you detect is not a contaminating co-purified protein.

What buffer should I use for diluting or reconstituting recombinant Serpin A-12 for cell-based or biochemical assays?

Recombinant Serpin A-12 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol. For biochemical inhibition assays, dilute directly into your assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl is fully compatible). For cell-based or adipokine-treatment experiments, buffer-exchange into PBS using a 10 kDa MWCO spin concentrator to remove glycerol before addition to cell culture media. Avoid diluting more than 1:20 into low-ionic-strength buffers without carrier protein (0.1% BSA), as serpins can adsorb to plastic at sub-nanomolar concentrations.

What are the storage and shelf life recommendations for recombinant Serpin A-12 to preserve inhibitory activity?

Store at -20 °C in the single-use aliquots provided. Repeated freeze-thaw cycles degrade serpin inhibitory activity disproportionately relative to total protein, because even partial RCL cleavage or loop insertion during denaturation produces latent or cleaved forms that are antigenically intact but functionally inert. Under recommended storage conditions, inhibitory activity is stable for at least 12 months. If working aliquots are needed, keep at 4 °C for no more than 5–7 days. Confirm functional integrity before key experiments by running a KLK7 inhibition assay alongside a reference aliquot stored from first thaw.

Validation imagery coming soon

Western blot validation figures for REC-SerpinA12 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →